ENDOMETRIAL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for endometrial cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug called ACR-368, given alone or with a low dose of chemotherapy, in people with endometrial cancer. The goal is to see if the drug can shrink tumors. About 400 participants will join this Phase 2 trial to check safety and effectiveness.
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New hope for advanced cancers? early trial launches for APL-5125
Disease control Recruiting nowThis study tests a new drug called APL-5125 in about 100 adults with advanced solid tumors, including colorectal, pancreatic, and ovarian cancers. The goal is to check safety and see if the drug can shrink tumors. Participants must have tried standard treatments first.
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
Immunotherapy double punch may beat single drug for returning uterine cancer
Disease control Recruiting nowThis study is for people with a type of recurrent endometrial cancer that has a specific DNA repair problem (dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against nivolumab alone to see which shrinks tumors better. About 81 participants wi…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC